NCT00387907View on ClinicalTrials.gov

Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Advanced Breast CancerBreast CancerMetastatic Breast Cancer
Interventions
DRUG

larotaxel (XRP9881)

administered as a 1-hour IV infusion on Day 1 of every 3 weeks (q3w)

DRUG

trastuzumab

administered as a 90-minute IV infusion on Day 1 of every week (qw)

Trial Locations (1)

19355

Sanofi-Aventis Administrative Office, Malvern

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY